MA49265A - Hydrogel cross-linked hyaluronic acid prodrug compositions and methods - Google Patents

Hydrogel cross-linked hyaluronic acid prodrug compositions and methods

Info

Publication number
MA49265A
MA49265A MA049265A MA49265A MA49265A MA 49265 A MA49265 A MA 49265A MA 049265 A MA049265 A MA 049265A MA 49265 A MA49265 A MA 49265A MA 49265 A MA49265 A MA 49265A
Authority
MA
Morocco
Prior art keywords
methods
hyaluronic acid
linked hyaluronic
acid prodrug
hydrogel cross
Prior art date
Application number
MA049265A
Other languages
English (en)
Inventor
Patrick Koenig
Nicola Bisek
Germaine Fuh
Thomas Knappe
Burkhardt Laufer
Chingwei Vivian Lee
Harald Rau
Sebastian Stark
Tobias Voigt
Samuel Weisbrod
Daniela Bumbaca Yadav
Original Assignee
Ascendis Pharma As
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendis Pharma As, Genentech Inc filed Critical Ascendis Pharma As
Publication of MA49265A publication Critical patent/MA49265A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA049265A 2017-03-22 2018-03-22 Hydrogel cross-linked hyaluronic acid prodrug compositions and methods MA49265A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762475094P 2017-03-22 2017-03-22

Publications (1)

Publication Number Publication Date
MA49265A true MA49265A (fr) 2020-02-05

Family

ID=61906882

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049265A MA49265A (fr) 2017-03-22 2018-03-22 Hydrogel cross-linked hyaluronic acid prodrug compositions and methods

Country Status (13)

Country Link
US (3) US11642415B2 (fr)
EP (1) EP3600441A1 (fr)
JP (2) JP7216006B2 (fr)
KR (2) KR102715397B1 (fr)
CN (1) CN110891611B (fr)
AR (1) AR111190A1 (fr)
AU (1) AU2018240375C1 (fr)
IL (1) IL269506B2 (fr)
MA (1) MA49265A (fr)
SG (2) SG10202107829YA (fr)
TW (1) TWI857935B (fr)
WO (1) WO2018175788A1 (fr)
ZA (1) ZA201905930B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015200905A2 (fr) 2014-06-28 2015-12-30 Oligasis, Llc Doubles antagonistes de pdgf/vegf
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
JP7216006B2 (ja) * 2017-03-22 2023-01-31 ジェネンテック， インコーポレイテッド ヒドロゲル架橋ヒアルロン酸プロドラッグ組成物及び方法
CA3092588A1 (fr) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Anticorps anti-il-6 et constructions de fusion et conjugues associes
CA3093083A1 (fr) 2018-03-28 2019-10-03 Ascendis Pharma A/S Conjugues
US12565525B2 (en) 2018-03-28 2026-03-03 Ascendis Pharma Oncology Division A/S IL-2 conjugates
CA3114272A1 (fr) * 2018-09-26 2020-04-02 Ascendis Pharma A/S Hydrogels degradables d'acide hyaluronique
SG11202104966XA (en) 2019-01-04 2021-06-29 Ascendis Pharma Oncology Div A/S Sustained local drug levels for innate immune agonists
AU2020205029A1 (en) 2019-01-04 2021-06-24 Ascendis Pharma Oncology Division A/S Minimization of systemic inflammation
SG11202105835YA (en) 2019-01-04 2021-07-29 Ascendis Pharma Oncology Div A/S Conjugates of pattern recognition receptor agonists
EP3906018A1 (fr) 2019-01-04 2021-11-10 Ascendis Pharma Oncology Division A/S Induction d'une inflammation locale soutenue
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
WO2020254612A1 (fr) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Composés inhibiteurs de tyrosine kinases à libération contrôlée présentant des propriétés pharmacodynamiques localisées
WO2020254607A1 (fr) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Composés anti-ctla4 à propriétés pd localisées
WO2020254617A1 (fr) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Composés anti-ctla4 présentant des propriétés pharmacocinétiques localisées
TW202114738A (zh) 2019-06-21 2021-04-16 丹麥商阿仙帝斯製藥公司 抗ctla4結合物
WO2020254613A1 (fr) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Composés inhibiteurs de tyrosine kinase à libération contrôlée présentant des propriétés pharmacocinétiques localisées
CA3143278A1 (fr) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Conjugues inhibiteur de tyrosine kinase
CA3157509A1 (fr) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Procedes de traitement d'un trouble oculaire
CA3161098A1 (fr) 2020-01-03 2021-07-08 Ascendis Pharma A/S Conjugues subissant des rearrangements intramoleculaires
WO2021224169A1 (fr) 2020-05-04 2021-11-11 Ascendis Pharma A/S Irradiation d'hydrogel
CA3178074A1 (fr) 2020-06-03 2021-12-09 Nina Gunnarsson Sequences d'il-2 et leurs utilisations
GB202011993D0 (en) 2020-07-31 2020-09-16 Adc Therapeutics Sa ANTI-IL 13Ra2 antibodies
AU2021335032A1 (en) 2020-08-28 2023-03-09 Ascendis Pharma Oncology Division A/S Glycosylated IL-2 proteins and uses thereof
EP4314035A1 (fr) 2021-04-01 2024-02-07 Ascendis Pharma A/S Utilisation d'une hormone de croissance à action prolongée pour le traitement de maladies induites par une inflammation
WO2023001288A1 (fr) * 2021-07-23 2023-01-26 百奥泰生物制药股份有限公司 Antagoniste de l'intégrine gpiib/iiia et son application en combinaison avec un anticorps anti-vegf
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
JP2024546134A (ja) 2021-12-13 2024-12-17 アセンディス ファーマ オンコロジー ディヴィジョン エー／エス Ｔｌｒ７／８アゴニストを用いたがん治療
TW202400244A (zh) * 2022-04-15 2024-01-01 美商瓦利托爾有限公司 經純化之多價蛋白質玻尿酸聚合物結合物
CN115389681B (zh) * 2022-11-01 2023-01-20 常州百瑞吉生物医药有限公司 一种巯基化透明质酸衍生物中二硫苏糖醇残留的检测方法
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
TW202430223A (zh) 2023-01-05 2024-08-01 丹麥商阿仙帝斯眼科製藥有限公司 用於治療眼部病症之藥物結合物
TW202434299A (zh) 2023-01-05 2024-09-01 丹麥商阿仙帝斯製藥公司 製造水凝膠微球之方法
IL323019A (en) 2023-03-06 2025-10-01 Ascendis Pharma As Drug compounds with an albumin-binding moiety
WO2026002095A1 (fr) * 2024-06-26 2026-01-02 Coval Biopharma (Shanghai) Co., Ltd. Système d'administration de médicament pour la libération contrôlée localement d'agents thérapeutiques et ses utilisations
WO2026112108A1 (fr) * 2024-11-20 2026-05-28 Valitor, Inc. Conjugués protéiques multivalents

Family Cites Families (236)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4716224A (en) 1984-05-04 1987-12-29 Seikagaku Kogyo Co. Ltd. Crosslinked hyaluronic acid and its use
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4937270A (en) 1987-09-18 1990-06-26 Genzyme Corporation Water insoluble derivatives of hyaluronic acid
EP0326111A3 (fr) 1988-01-29 1989-12-27 New York Blood Center, Inc. Dérivés de peptide rendus immunogéniques lors de l'administration d'un alun comme adjuvant
IT1219587B (it) 1988-05-13 1990-05-18 Fidia Farmaceutici Polisaccaridi carbossiilici autoreticolati
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
SE8900422D0 (sv) 1989-02-08 1989-02-08 Pharmacia Ab Tvaerbundna hyaluronatgeler samt foerfarande foer framstaellning av dessa
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5356883A (en) 1989-08-01 1994-10-18 Research Foundation Of State University Of N.Y. Water-insoluble derivatives of hyaluronic acid and their methods of preparation and use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
JP3046623B2 (ja) 1990-06-14 2000-05-29 ヴィタフォア コーポレイション ポリウレタン―生体高分子複合体
ES2084825T3 (es) 1990-07-26 1996-05-16 Monsanto Co Procedimiento de preparacion de poliamidas entrecruzadas.
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US5144088A (en) 1991-04-26 1992-09-01 Aristech Chemical Corporation Manufacture of neopentyl glycol (I)
EP0590058B1 (fr) 1991-06-14 2003-11-26 Genentech, Inc. ANTICORP HUMANISE specifique pour heregulin
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP0604580A1 (fr) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION DANS L'E. COLI DE FRAGMENTS D'ANTICORPS POSSEDANT AU MOINS UNE CYSTEINE PRESENTE SOUS FORME D'UN THIOL LIBRE, ET LEUR UTILISATION DANS LA PRODUCTION D'ANTICORPS BIFONCTIONNELS F(ab') 2?
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993009176A2 (fr) 1991-10-29 1993-05-13 Clover Consolidated, Limited Polysaccharides, polycations et lipides reticulables destines a l'encapsulation et la liberation de medicaments
WO1993008829A1 (fr) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
CA2372813A1 (fr) 1992-02-06 1993-08-19 L.L. Houston Proteine fixatrice biosynthetique pour marqueur du cancer
US5514379A (en) 1992-08-07 1996-05-07 The General Hospital Corporation Hydrogel compositions and methods of use
GB9216925D0 (en) 1992-08-10 1992-09-23 Royal Holloway Microspheres of polyhydroxylic materials
JP3107488B2 (ja) 1993-09-29 2000-11-06 株式会社資生堂 架橋ヒアルロン酸を用いた徐放性製剤及び塞栓剤
US5658592A (en) 1994-05-13 1997-08-19 Kuraray Co., Ltd. Medical crosslinked polymer gel of carboxylic polysaccharide and diaminoalkane
US6063396A (en) 1994-10-26 2000-05-16 Houston Biotechnology Incorporated Methods and compositions for the modulation of cell proliferation and wound healing
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5690961A (en) 1994-12-22 1997-11-25 Hercules Incorporated Acidic polysaccharides crosslinked with polycarboxylic acids and their uses
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
IT1281886B1 (it) 1995-05-22 1998-03-03 Fidia Advanced Biopolymers Srl Processo per la preparazione di idrogel ottenuti da derivati chimici dell'acido ialuronico mediante irradiazioni ultraviolette e loro
US5612321A (en) 1995-06-22 1997-03-18 Hercules Incorporated Antioxidant grafted polysaccharides
JP3130234B2 (ja) 1995-09-29 2001-01-31 デンセイ・ラムダ株式会社 インバータ装置
WO1997028828A1 (fr) 1996-02-09 1997-08-14 Amgen Boulder Inc. Composition comprenant un inhibiteur de l'interleukine 1 et un polymere a liberation controlee
US6303585B1 (en) 1997-07-03 2001-10-16 Orquest, Inc. Cross-linked polysaccharide drug carrier
JPH1133104A (ja) 1997-07-16 1999-02-09 Res Inst For Prod Dev 生体組織への接着性を有する医用材料
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
WO1999029888A1 (fr) 1997-12-05 1999-06-17 The Scripps Research Institute Humanisation d'anticorps murins
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
WO1999059603A1 (fr) 1998-05-20 1999-11-25 Chugai Seiyaku Kabushiki Kaisha Medicaments contre les affections articulaires lies a l'acide hyaluronique
ITPD980169A1 (it) 1998-07-06 2000-01-06 Fidia Advanced Biopolymers Srl Ammidi dell'acido ialuronico e dei suoi derivati e processo per la loro preparazione.
US6630457B1 (en) 1998-09-18 2003-10-07 Orthogene Llc Functionalized derivatives of hyaluronic acid, formation of hydrogels in situ using same, and methods for making and using same
JP2000119196A (ja) 1998-10-07 2000-04-25 Menicon Co Ltd 眼科用薬剤徐放材及びその製造方法
IT1303735B1 (it) 1998-11-11 2001-02-23 Falorni Italia Farmaceutici S Acidi ialuronici reticolati e loro usi medici.
EP1137373A4 (fr) 1998-12-04 2004-05-19 Chandrashekhar P Pathak Polymeres reticules biocompatibles
CA2365767A1 (fr) 1999-03-15 2000-09-21 Trustees Of Boston University Inhibition d'une angiogenese
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
WO2001040314A1 (fr) 1999-11-26 2001-06-07 The Regents Of The University Of Michigan Hydrogels reticules de maniere reversible
JP2003516755A (ja) 1999-12-15 2003-05-20 ジェネンテック・インコーポレーテッド ショットガン走査、すなわち機能性タンパク質エピトープをマッピングするための組み合わせ方法
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
ATE298256T1 (de) 2000-07-31 2005-07-15 Iscience Corp Biomaterial in form von mikropartikeln von hyaluronsaure zur medizinischen verwendung
IT1317358B1 (it) 2000-08-31 2003-06-16 Fidia Advanced Biopolymers Srl Derivati cross-linkati dell'acido ialuronico.
DK1355566T3 (da) 2000-12-18 2013-03-04 Univ Texas Lokal regional kemoterapi og radioterapi ved anvendelse af hydrogel in situ
WO2002068383A2 (fr) 2001-02-22 2002-09-06 Anika Therapeutics, Inc. Hyaluronane à modification thiol
ITMI20011238A1 (it) 2001-06-12 2002-12-12 Bartholdy Consultadoria E Serv Polimeri polisaccaridici di origine naturale coniugati chimicamente asostanze farmacologicamente o biologicamente attive e loro proprieta'
ITPD20020064A1 (it) 2002-03-12 2003-09-12 Fidia Advanced Biopolymers Srl Derivati esterei dell'acido ialuronico per la preparazione di idrogelda utilizzare in campo biomedico, sanitario e chirurgico e come sistem
US7056901B2 (en) 2002-03-29 2006-06-06 The Regents Of The University Of California Microgel particles for the delivery of bioactive materials
AU2003221078A1 (en) 2002-04-08 2003-10-20 Denki Kagaku Kogyo Kabushiki Kaisha Therapeutic composition for bone infectious disease
US7375234B2 (en) 2002-05-30 2008-05-20 The Scripps Research Institute Copper-catalysed ligation of azides and acetylenes
EP1513879B1 (fr) 2002-06-03 2018-08-22 Genentech, Inc. Bibliotheques de phages et anticorps synthetiques
KR100507545B1 (ko) 2002-09-03 2005-08-09 주식회사 엘지생명과학 히알루론산 유도체 및 그의 제조방법
JP5156890B2 (ja) 2002-09-11 2013-03-06 独立行政法人物質・材料研究機構 高分子架橋体及びその製造方法
WO2004046200A1 (fr) 2002-11-21 2004-06-03 Chugai Seiyaku Kabushiki Kaisha Excipient pour medicament a liberation retardee
CA2509382A1 (fr) 2002-12-17 2004-07-08 Todd C. Zion Systemes reagissant a des stimulis pour l'administration regulee de medicaments
AU2004205631A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
CA2513483C (fr) 2003-01-17 2011-11-29 Cornell Research Foundation, Inc. Microspheres hydrogel injectables de systeme aqueux a deux phases
US7332164B2 (en) 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
WO2004089280A2 (fr) 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd. Medicaments pegyles reversibles
AU2003901834A0 (en) 2003-04-17 2003-05-01 Clearcoll Pty Ltd Cross-linked polysaccharide compositions
JP2004323454A (ja) 2003-04-25 2004-11-18 Chisso Corp 薬剤
JP4869066B2 (ja) 2003-04-25 2012-02-01 ケイオウエス ライフ サイエンスイズ，インコーポレイテッド 丈夫な超多孔性ヒドロゲルの形成技術
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005044853A2 (fr) * 2003-11-01 2005-05-19 Genentech, Inc. Anticorps anti-vegf
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
WO2005034852A2 (fr) 2003-08-26 2005-04-21 Gel-Del Technologies, Inc. Biomateriaux et biocoacervats proteiniques, leurs procedes de fabrication et d'utilisation
US7690003B2 (en) 2003-08-29 2010-03-30 Fuller Jeffrey C System and method for increasing data throughput using thread scheduling
US8124120B2 (en) 2003-12-22 2012-02-28 Anika Therapeutics, Inc. Crosslinked hyaluronic acid compositions for tissue augmentation
EP1576952A1 (fr) 2004-03-18 2005-09-21 OctoPlus Technologies B.V. Microsphères d'hydrogel avec un profil amélioré de libération
CA2786794C (fr) 2004-03-23 2017-09-12 Complex Biosystems Gmbh Agent reactif liant de promedicament a cascade polymerique aromatique
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
US8293890B2 (en) 2004-04-30 2012-10-23 Advanced Cardiovascular Systems, Inc. Hyaluronic acid based copolymers
US20050244472A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
GB0411583D0 (en) 2004-05-24 2004-06-23 Univ Bath Process
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
WO2006113668A1 (fr) 2005-04-15 2006-10-26 University Of South Florida Procede de delivrance d’un medicament par voie transdermique en utilisant des nanoparticules d’acide hyaluronique
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
EP1905456A4 (fr) 2005-07-06 2010-12-22 Seikagaku Kogyo Co Ltd Gel dérivé de l'acide hyaluronique photoréticulé contenant un médicament
US8679536B2 (en) 2005-08-24 2014-03-25 Actamax Surgical Materials, Llc Aldol-crosslinked polymeric hydrogel adhesives
KR20080080481A (ko) 2005-09-02 2008-09-04 콜바르 라이프사이언스 리미티드 교차-결합된 다당류 및 단백질 매트릭스 및 그의 제조 방법
AU2006292752A1 (en) 2005-09-15 2007-03-29 University Of Utah Research Foundation Polymeric compositions and methods of making and using thereof
US20090130769A1 (en) 2005-09-21 2009-05-21 Universiteit Van Amsterdam Novel Cross-Linkers For Obtaining Structure Information On Molecule Complexes
US20080306022A1 (en) 2005-10-12 2008-12-11 Kenji Miyamoto Agent for Applying to Mucosa and Method for the Production Thereof
WO2007047997A2 (fr) 2005-10-19 2007-04-26 Smartcells, Inc. Procedes de reduction de la mitogenicite de compositions de lectine
EP1957531B1 (fr) 2005-11-07 2016-04-13 Genentech, Inc. Polypeptides de liaison comprenant des sequences diversifiees et des sequences consensus hypervariables vh/vl
WO2007064919A2 (fr) 2005-12-02 2007-06-07 Genentech, Inc. Polypeptides de liaison avec des sequences de diversite limitees
EP1968498A2 (fr) 2005-12-14 2008-09-17 Anika Therapeutics Inc. Implant meniscal de derives d'acide hyaluronique destine au traitement de defauts meniscaux
US7879818B2 (en) 2005-12-23 2011-02-01 Janos Borbely Hyaluronic acid-based cross-linked nanoparticles
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
AU2007240613B2 (en) 2006-04-20 2013-11-28 University Of Utah Research Foundation Polymeric compositions and methods of making and using thereof
EP2016101A2 (fr) 2006-05-09 2009-01-21 Genentech, Inc. Polypeptides de liaison à squelettes optimisés
EP2471816A1 (fr) 2006-08-30 2012-07-04 Genentech, Inc. Anticorps multi-spécifiques
ITMI20061726A1 (it) 2006-09-11 2008-03-12 Fidia Farmaceutici Derivati crosslinkati a base di acido ialuronico reticolato via click chemistry
WO2008034122A2 (fr) 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Segments de liaison biodégradables à base d'ester encombré pour distribution d'oligonuclotides
US20080089923A1 (en) 2006-09-29 2008-04-17 Burkstrand Michael J Biodegradable ocular implants and methods for treating ocular conditions
EP1942117A1 (fr) 2006-12-29 2008-07-09 Sigea S.R.L. Dérivés de polysaccharides acides
KR20080073419A (ko) 2007-02-06 2008-08-11 주식회사 핸슨바이오텍 의료용 히알루론산 유도체 마이크로비드 및 이의 제조 방법
EP1992364A1 (fr) 2007-05-16 2008-11-19 Biosuma S.r.l. Dérivés phosphatés ou bisphosphanotés de polysaccharides carboxylés, éventuellement réticulés, et leur préparation et leurs utilisations biomédicales
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
JP2010533202A (ja) 2007-07-11 2010-10-21 エンゾン ファーマシューティカルズ，インコーポレーテッド 多置換芳香族部分を含むポリマー性薬剤送達システム
US8318695B2 (en) 2007-07-30 2012-11-27 Allergan, Inc. Tunably crosslinked polysaccharide compositions
EP2090592A1 (fr) 2007-07-31 2009-08-19 OctoPlus Sciences B.V. Hydrogels biodégradables obtenus par cycloaddition (chimie click)
KR101062320B1 (ko) 2007-08-01 2011-09-05 포항공과대학교 산학협력단 가교결합성 히알루론산 유도체 제조방법 및 그 히알루론산유도체의 가교결합물
MX2010001629A (es) 2007-08-10 2010-08-09 Alessandro Sannino Hidrogeles de polimero y metodos de preparacion de los mismos.
US20100210509A1 (en) 2007-10-09 2010-08-19 Postech Academy-Industry Foundation Long acting hyaluronic acid - peptide conjugate
JP5579609B2 (ja) 2007-10-11 2014-08-27 アンセルム（アンスチチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル） 組織工学、細胞培養、および細胞送達用の多孔質足場の調製方法
SG185281A1 (en) 2007-10-11 2012-11-29 Inserm Inst Nat De Sante Et De La Rech Medicale Method for preparing porous scaffold for tissue engineering
US20090143348A1 (en) 2007-11-30 2009-06-04 Ahmet Tezel Polysaccharide gel compositions and methods for sustained delivery of drugs
US8394782B2 (en) 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having increased longevity
WO2009077399A1 (fr) 2007-12-19 2009-06-25 Evonik Goldschmidt Gmbh Acide hyaluronique réticulé en émulsion
CA2706183A1 (fr) 2007-12-21 2009-07-02 Encecor Ab Hydrogel reticule contenant une substance active
EP3663318A1 (fr) 2008-01-07 2020-06-10 Amgen Inc. Procédé de fabrication de molécules hétérodimères fc d'anticorps utilisant les effets de conduite électrostatique
LT2237799T (lt) 2008-02-01 2019-07-25 Ascendis Pharma A/S Provaistas, apimantis besiskaidantį linkerį
CN101538377A (zh) 2008-03-20 2009-09-23 上海昊海生物科技有限公司 一种交联透明质酸凝胶及其制备方法
IE20080211A1 (en) 2008-03-20 2009-11-25 Nat Univ Ireland Biodegradable nanoshells for delivery of therapeutic and/or imaging molecules
JP2011517451A (ja) 2008-03-28 2011-06-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ポリペプチド−ポリマー抱合体およびその使用方法
WO2009143412A2 (fr) 2008-05-23 2009-11-26 Enzon Pharmaceuticals, Inc. Systèmes polymères contenant un lieur disulfure intracellulaire libérable pour la délivrance d’oligonucléotides
US8821870B2 (en) 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
US8357795B2 (en) 2008-08-04 2013-01-22 Allergan, Inc. Hyaluronic acid-based gels including lidocaine
GB0816496D0 (en) 2008-09-10 2008-10-15 Zhao Xiaobin Hyaluronic acid cryogel
CN101721349B (zh) 2008-10-16 2011-07-20 常州百瑞吉生物医药有限公司 可注射原位交联水凝胶及其制备方法和用途
US20100098772A1 (en) 2008-10-21 2010-04-22 Allergan, Inc. Drug delivery systems and methods for treating neovascularization
ITRM20080636A1 (it) 2008-11-28 2010-05-29 Univ Palermo Procedimento per la produzione di derivati funzionalizzati dell acido ialuronico e relativi idrogeli.
US8133979B2 (en) 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
US11090387B2 (en) 2008-12-22 2021-08-17 The Trustees Of The University Of Pennsylvania Hydrolytically degradable polysaccharide hydrogels
FR2945949B1 (fr) 2009-05-26 2011-05-13 Anteis Sa Hydrogel injectable permettant une supplementation en glycerol dans la peau sur le long terme.
EA201190273A1 (ru) * 2009-05-28 2012-12-28 Глаксо Груп Лимитед Комбинация антагониста tnf-альфа и антагониста vegf для применения в лечении или предупреждении заболеваний глаз
WO2010138074A1 (fr) 2009-05-29 2010-12-02 Hilborn Joens Systèmes d'administration à base d'acide hyaluronique
IT1399351B1 (it) 2009-06-16 2013-04-16 Fidia Farmaceutici Procedimento per la sintesi di coniugati di glicosamminoglicani (gag) con molecole biologicamente attive, coniugati polimerici e usi relativi
KR101091028B1 (ko) 2009-07-02 2011-12-09 아주대학교산학협력단 체내 주입형 하이드로젤 및 이의 생의학적 용도
EP2448604B1 (fr) 2009-07-02 2016-03-23 Actamax Surgical Materials LLC Adhesif de type hydrogel pour tissu a usage medical
LT2459220T (lt) 2009-07-31 2020-12-28 Ascendis Pharma A/S Biologiškai suyrantys vandenyje netirpūs hidrogeliai polietilenglikolio pagrindu
US9173953B2 (en) 2009-07-31 2015-11-03 Ascendis Pharma As Prodrugs containing an aromatic amine connected by an amido bond to a linker
SG178369A1 (en) 2009-08-11 2012-04-27 Agency Science Tech & Res Particulate hyaluronic acid formulations for cellular delivery of bioactive agents
JO3008B1 (ar) 2009-08-13 2016-09-05 Seikagaku Kogyo Co Ltd تركيب صيدلي لتخفيف الألم
KR101103423B1 (ko) 2009-09-04 2012-01-06 아주대학교산학협력단 생체 주입형 조직 접착성 하이드로젤 및 이의 생의학적 용도
WO2011066417A2 (fr) * 2009-11-24 2011-06-03 Carnegie Mellon University Anticorps et conjugués pour des modulateurs d'angiogenèse
EP2963111A1 (fr) 2009-12-22 2016-01-06 Lifebond Ltd Modification de réticulation enzymatique permettant de réguler les propriétés de matrices réticulées
CN102724967A (zh) 2009-12-31 2012-10-10 安龙制药公司 包括可释放的脲连接体的含芳香胺化合物的聚合缀合物
EP2525829A1 (fr) 2010-01-22 2012-11-28 Ascendis Pharma A/S Lieurs de promédicaments à base de dipeptides pour des médicaments à teneur en amine aromatique
EP2525831B1 (fr) 2010-01-22 2019-05-15 Ascendis Pharma A/S Liens de promédicaments à base de carbamates liés à un support
US9062094B2 (en) 2010-01-22 2015-06-23 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
CA2791050A1 (fr) 2010-03-01 2011-09-09 Tautona Group Lp Fils d'acide hyaluronique reticule et leurs methodes d'utilisation
JP2013523752A (ja) 2010-03-29 2013-06-17 エボニック デグサ コーポレイション 局所投与部位における医薬組成物の保持改善のための組成物および方法
US8859629B2 (en) 2010-04-27 2014-10-14 Synaffix B.V. Fused cyclooctyne compounds and their use in metal-free click reactions
WO2011140393A1 (fr) 2010-05-05 2011-11-10 Prolynx Llc Libération contrôlée à partir de conjugués macromoléculaires
EP2566334B1 (fr) 2010-05-05 2018-04-18 Prolynx, LLC Supports solides pour la libération contrôlée de médicaments
WO2011148116A2 (fr) 2010-05-27 2011-12-01 Laboratoire Idenov Acide hyaluronique modifie, procede de fabrication et utilisations
WO2011163069A2 (fr) 2010-06-21 2011-12-29 The Trustees Of The University Of Pennsylvania Libération déclenchée par des protéases, de molécules présentes dans des hydrogels
JP5937070B2 (ja) 2010-06-22 2016-06-22 ウニヴェルシテ ド ルアンＵｎｉｖｅｒｓｉｔｅ Ｄｅ Ｒｏｕｅｎ ３ｄ細胞培養に用いる改良された架橋ヒアルロナンヒドロゲル
IT1401498B1 (it) 2010-07-30 2013-07-26 Mero Srl Idrogelo a base di acido ialuronico e suo uso in ortopedia
US20130274222A1 (en) 2010-10-20 2013-10-17 Tautona Group Lp Threads of cross-linked hyaluronic acid and methods of preparation and use thereof
FR2967677B1 (fr) 2010-11-18 2014-05-16 Centre Nat Rech Scient Derives de polysaccharides comprenant un motif alcene et reaction de couplage par chimie thio-clic
US20140038826A1 (en) 2011-01-28 2014-02-06 The Regents Of The University Of Colorado, A Body Corporate Covalently cross linked hydrogels and methods of making and using same
EP2682409B1 (fr) 2011-03-03 2017-07-05 Chugai Seiyaku Kabushiki Kaisha Dérivé d'acide hyaluronique modifié par l'acide aminocarbonique
CZ304072B6 (cs) 2011-04-26 2013-09-25 Contipro Biotech S.R.O. Amfoterní materiál na bázi sítované kyseliny hyaluronové, zpusob jeho prípravy, materiály obsahující aktivní cinidla uzavrené v síti hyaluronanu, zpusob jejich prípravy a jejich pouzití
ES2685327T3 (es) 2011-04-28 2018-10-08 President And Fellows Of Harvard College Armazones tridimensionales macroscópicos preformados inyectables para administración mínimamente invasiva
US20140256831A1 (en) 2011-05-31 2014-09-11 The University Of Tokyo Hydrogel and method for producing same
RU2624239C2 (ru) 2011-06-03 2017-07-03 Аллерган, Инк. Составы кожного наполнителя, включая антиоксиданты
CN102226009B (zh) 2011-06-09 2013-04-10 西安力邦制药有限公司 一种交联透明质酸凝胶的制备方法
WO2012171335A1 (fr) 2011-06-16 2012-12-20 The Hong Kong University Of Science And Technology Molécule contenant de multiples groupes vinylsulfone
EP3643306A3 (fr) 2011-08-12 2020-08-26 Ascendis Pharma A/S Promédicaments liés à un support dotés de liaisons ester carboxylique réversibles
US9044515B2 (en) 2011-09-06 2015-06-02 University Of Delaware Chemical conjugates for targeted degradation under reducing conditions
SG11201400444VA (en) 2011-09-07 2014-04-28 Prolynx Llc Hydrogels with biodegradable crosslinking
WO2013036857A1 (fr) 2011-09-07 2013-03-14 Prolynx Llc Coupleurs au sulfone
US20130066063A1 (en) 2011-09-09 2013-03-14 John Cooke Hodges Bicyclo[6.1.0]non-4-yne regents for chemical modification of oligonucleotides
EP3243533B1 (fr) 2011-10-11 2020-06-17 Allergan Holdings France S.A.S. Fils d'acide hyaluronique réticulé et leurs procédés d'utilisation
MX2014003993A (es) * 2011-10-12 2014-08-08 Ascendis Pharma Ophthalmology Division As Prevencion y tratamiento de condiciones oculares.
KR20140059238A (ko) 2011-11-11 2014-05-15 미바 메디컬 아이엔시. 주사 시술용 보형물
US20140107025A1 (en) 2012-04-16 2014-04-17 Jade Therapeutics, Llc Ocular drug delivery system
EP2841109B1 (fr) 2012-04-25 2026-04-15 Ascendis Pharma A/S Prodrogues de médicaments comprenant un hydroxyle
KR101374271B1 (ko) 2012-05-02 2014-03-14 주식회사 제네웰 히알루론산 에폭사이드 가교체 및 그 제조방법
EP2852664B1 (fr) 2012-05-18 2017-09-06 Medical Research Council Procédés d'incorporation d'un acide aminé comprenant un groupe bcn dans un polypeptide à l'aide d'un codon orthogonal codant pour ledit acide et d'une pylrs synthase orthogonale
SI3495387T1 (sl) 2012-07-13 2021-12-31 Roche Glycart Ag Bispecifična protitelesa proti VEGF/proti ANG-2 in njihova uporaba pri zdravljenju bolezni očesnih žil
CZ304512B6 (cs) 2012-08-08 2014-06-11 Contipro Biotech S.R.O. Derivát kyseliny hyaluronové, způsob jeho přípravy, způsob jeho modifikace a použití
US9827321B2 (en) 2012-08-14 2017-11-28 The Trustees Of The University Of Pennsylvania Stabilizing shear-thinning hydrogels
KR101445265B1 (ko) 2012-09-18 2014-09-30 포항공과대학교 산학협력단 히알루론산-핵산 접합체 및 이를 포함하는 핵산 전달용 조성물
WO2014048564A1 (fr) 2012-09-25 2014-04-03 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Nouveaux réticulants destinés à des hydrogels, hydrogels comprenant ces réticulants et leurs applications
DK2906246T3 (da) 2012-10-11 2023-09-04 Ascendis Pharma Ophthalmology Div A/S VEGF-neutraliserende prodrugs omfattende ranibizumab til behandling af okulære tilstande, der er kendetegnet ved okulær neovaskularisering
CN102942699B (zh) 2012-10-26 2014-07-02 暨南大学 一种自增强双交联透明质酸水凝胶及其制备方法
CN102911380B (zh) 2012-10-29 2015-03-18 北京爱美客生物科技有限公司 透明质酸与生物可降解高分子改性材料及制备方法
WO2014169301A1 (fr) 2013-04-12 2014-10-16 Bui The Duy Systèmes et procédés pour administrer de l'acide hyaluronique réticulé à un patient
EP2727597A1 (fr) 2012-11-06 2014-05-07 Centre National de la Recherche Scientifique (CNRS) Hydrogel sensible au glucose comprenant de l'acide hyaluronique (ha) greffé pba
ITPD20120360A1 (it) 2012-11-30 2014-05-31 Fidia Farmaceutici "nuovi geli viscoelastici in chirurgia oftalmica"
KR20150095684A (ko) * 2012-12-18 2015-08-21 노파르티스 아게 히알루로난에 결합하는 펩티드 태그를 이용하는 조성물 및 방법
WO2014096257A1 (fr) 2012-12-19 2014-06-26 Novozymes Biopharma Dk A/S Éponge d'acide hyaluronique réticulé lyophilisée
US9498539B2 (en) 2012-12-27 2016-11-22 Molly Sandra Shoichet Affinity-based controlled release system
CN105007896B (zh) 2012-12-28 2019-04-09 雅培心血管系统公司 包含抗体的治疗组合物
EP2958947B1 (fr) 2013-02-20 2019-08-14 The University of Queensland Composé conjugué et applications associées
WO2014138897A1 (fr) 2013-03-14 2014-09-18 Anacoti Ltd. Dérivés d'acide hyaluronique
CN105188667A (zh) 2013-03-27 2015-12-23 佛多斯大学医学研究中心(C·H·U·V) 用于治疗和/或预防再狭窄的药物制剂
KR102049568B1 (ko) 2013-04-01 2019-11-27 삼성전자주식회사 히알루론산을 포함하는 핵산전달용 조성물
US20150190517A1 (en) 2013-04-12 2015-07-09 Miba Medical Inc. Systems and methods for delivering cross-linked halyuronic acid into a patient
WO2014169298A1 (fr) 2013-04-12 2014-10-16 Bui The Duy Réticulation in situ à contrôle temporel d'acide hyaluronique pendant une injection
WO2014169299A1 (fr) 2013-04-12 2014-10-16 Bui The Duy Catalyseur activé par température pour réticuler de l'acide hyaluronique pendant une injection
US11116849B2 (en) * 2013-04-22 2021-09-14 Ascendis Pharma A/S Hydrogel-linked prodrugs releasing tagged drugs
EP2988755A4 (fr) 2013-04-25 2016-11-30 Aluron Biopharma Inc Compositions d'acide hyaluronique réticulées
US10137199B2 (en) 2013-05-14 2018-11-27 Biotime, Inc. Thiolated hyaluronan-based hydrogels cross-linked using oxidized glutathione
FR3006689A1 (fr) 2013-06-11 2014-12-12 Benedicte Vincente Tauzin Procede de reticulation de l'acide hyaluronique; procede de preparation d'un hydrogel injectable; hydrogel obtenu; utilisation de l'hydroget obtenu
CA2914765A1 (fr) 2013-06-14 2014-12-18 Galderma S.A. Compositions renfermant de l'acide hyaluronique reticule et de la cyclodextrine
RU2640865C2 (ru) 2013-06-28 2018-01-12 Гальдерма С.А. Способ производства формованного продукта из поперечно-сшитой гиалуроновой кислоты
EP3016634A2 (fr) 2013-07-05 2016-05-11 Therakine Biodelivery GmbH Composition d'administration de médicament pour applications topiques et injections et formulations ophtalmiques, procédés de fabrication associés et procédés d'administration d'une composition d'administration de médicament
WO2015048408A1 (fr) 2013-09-27 2015-04-02 Virginia Tech Intellectual Properties, Inc. Dérivés de polysaccharide ayant subi une méthathèse croisée et procédés de préparation de ceux-ci
CA2925190C (fr) 2013-10-08 2021-10-12 Ascendis Pharma A/S Groupe protecteur comprenant une etiquette de purification
WO2015053281A1 (fr) 2013-10-08 2015-04-16 キユーピー株式会社 Produit réticulé d'acide hyaluronique modifié contenant des groupes carboxyméthyle et/ou de sel de celui-ci, et procédé pour le préparer
WO2015053282A1 (fr) 2013-10-08 2015-04-16 キユーピー株式会社 Produit réticulé d'acide hyaluronique modifié contenant des groupes carboxyméthyle et/ou sel de celui-ci, et procédé pour le préparer
US9782345B2 (en) 2013-10-17 2017-10-10 Jade Therapeutics, Inc. Ocular composition and method
KR101459070B1 (ko) 2013-12-09 2014-11-17 (주) 뉴메딕 지속성을 갖는 히알루론산 겔 조성물
RU2016133980A (ru) * 2014-01-23 2018-03-01 Экебиа Терапьютикс, Инк. Композиции и способы для лечения заболеваний глаз
ES2993327T3 (en) 2014-08-06 2024-12-27 Ascendis Pharma As Prodrugs comprising an aminoalkyl glycine linker
WO2016073157A1 (fr) 2014-11-06 2016-05-12 Genentech, Inc. Anticorps anti-ang2 et procédés d'utilisation de ces anticorps
SI3215530T1 (sl) 2014-11-07 2020-02-28 Sesen Bio, Inc. Izboljšana protitelesa IL-6
WO2016196124A2 (fr) 2015-05-29 2016-12-08 Ascendis Pharma Inc. Promédicaments comprenant un lieur de pyroglutamate
EP3302569A1 (fr) 2015-05-29 2018-04-11 Albatross Technologies Limited Acide hyaluronique réticulé pour l'administration de médicaments et préparation pharmaceutique utilisant celui-ci
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
JP6959912B2 (ja) 2015-09-23 2021-11-05 ジェネンテック， インコーポレイテッド 抗ｖｅｇｆ抗体の最適化変異体
KR102944785B1 (ko) 2015-12-09 2026-03-30 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 안구 질환 또는 장애의 치료 방법
AR110299A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico
JP7216006B2 (ja) * 2017-03-22 2023-01-31 ジェネンテック， インコーポレイテッド ヒドロゲル架橋ヒアルロン酸プロドラッグ組成物及び方法

Also Published As

Publication number Publication date
KR102715397B1 (ko) 2024-10-10
NZ757216A (en) 2026-01-30
US20230414770A1 (en) 2023-12-28
BR112019019658A2 (pt) 2020-04-22
TWI857935B (zh) 2024-10-11
IL269506B1 (en) 2023-12-01
RU2019133326A (ru) 2021-04-22
KR20200007776A (ko) 2020-01-22
IL269506A (en) 2019-11-28
AU2018240375A2 (en) 2020-03-05
JP7216006B2 (ja) 2023-01-31
AU2018240375C1 (en) 2024-02-01
EP3600441A1 (fr) 2020-02-05
IL269506B2 (en) 2024-04-01
JP2023058511A (ja) 2023-04-25
CN110891611A (zh) 2020-03-17
SG11201908547VA (en) 2019-10-30
AU2018240375B2 (en) 2023-08-03
ZA201905930B (en) 2024-01-31
US20250255973A1 (en) 2025-08-14
US12246070B2 (en) 2025-03-11
KR20240150530A (ko) 2024-10-15
AR111190A1 (es) 2019-06-12
CN110891611B (zh) 2024-03-29
RU2019133326A3 (fr) 2021-10-19
TW201842936A (zh) 2018-12-16
WO2018175788A1 (fr) 2018-09-27
AU2018240375A1 (en) 2019-09-26
JP2020515545A (ja) 2020-05-28
CA3055985A1 (fr) 2018-09-27
US11642415B2 (en) 2023-05-09
SG10202107829YA (en) 2021-08-30
US20200222547A1 (en) 2020-07-16

Similar Documents

Publication Publication Date Title
IL269506A (en) Hyaluronic acid cross-linked hydrogel preparations and methods
IL268970A (en) New preparations and methods
IL274702A (en) Compounds and Methods for Neurological Diseases
EP3209718A4 (fr) Compositions d'hydrogel imitant un tissu pour biofabrication
EP3142691A4 (fr) Méthodes et compositions de traitement de maladies auto-immunes et inflammatoires
EP3261626A4 (fr) Méthodes et compositions se rapportant à des implants biocompatibles
EP3129494A4 (fr) Compositions d'hydrogel destinées à être utilisées dans l'activation de la tubulogenèse
SG11201707876YA (en) Microalgal compositions and uses thereof
GB2578990B (en) Polymer compositions
GB202201860D0 (en) Novel methods and compositions
EP3122355A4 (fr) Compositions et procédés d'inhibition de la bmp
GB201707211D0 (en) Compositions and methods
EP3261644A4 (fr) Compositions et méthodes pour le traitement de dégradations de la rétine
EP3310385A4 (fr) Procédés et compositions de traitement de maladies fibrotiques
IL274524A (en) Preparations and methods for aquaculture
EP3238692A4 (fr) Composition d'hydrogel
GB201820018D0 (en) Therapeutic hydrogel compositions
WO2016141334A9 (fr) Compositions et méthodes de diagnostic et de traitement de maladies auto-immunes
EP3275945A4 (fr) Composition de formation d'hydrogel et hydrogel à haute résistance formé avec celle-ci
PL3292162T3 (pl) Kompozycje katalizatorów żelujących o opóźnionym działaniu i sposoby wytwarzania polimerów poliuretanowych
ZA202004533B (en) Skin-brightening compositions and methods
EP3618850A4 (fr) Compositions et méthodes de traitement de pathologies oculaires
PL3601406T3 (pl) Kompozycja polimeru polietero-epoksydowego
GB2537783B (en) Compositions used in treating inflammatory and autoimmune diseases
PL3297626T3 (pl) Kompozycja oftalmiczna zawierająca kwas liponowy i kwas hialuronowy